Select Page

Entitled “Sustainability and Innovation in Rare Cancer Management,“ the 2nd Annual EURACAN Conference, chaired by Prof Jean-Yves Blay and Prof Bass Hassan, offered an overview of the latest updates in rare cancers management. The conference covered multiple sessions over three days including: the Rare Cancer Pathway, facilitating communication between healthcare providers and patients, enabling technologies for rare cancer diagnosis, management and treatment; rare cancer drug development; payers, healthcare providers and patients’ perspectives.

INCA was represented by Cathy Bouvier, Jo Grey and Teodora Kolarova – European Patient Advocacy Groups (ePAGs) for the Neuroendocrine and Endocrine domains. At the Oxford meeting it has been asserted again that ePAGs’ role is instrumental to the success of EURACAN, whose aim is to facilitate timely diagnosis and access to treatments for patients anywhere in the EU.